Regulatory Oversight of Cell and Gene Therapy Products in Canada
- PMID: 26374212
- DOI: 10.1007/978-3-319-18618-4_3
Regulatory Oversight of Cell and Gene Therapy Products in Canada
Abstract
Health Canada regulates gene therapy products and many cell therapy products as biological drugs under the Canadian Food and Drugs Act and its attendant regulations. Cellular products that meet certain criteria, including minimal manipulation and homologous use, may be subjected to a standards-based approach under the Safety of Human Cells, Tissues and Organs for Transplantation Regulations. The manufacture and clinical testing of cell and gene therapy products (CGTPs) presents many challenges beyond those for protein biologics. Cells cannot be subjected to pathogen removal or inactivation procedures and must frequently be administered shortly after final formulation. Viral vector design and manufacturing control are critically important to overall product quality and linked to safety and efficacy in patients through concerns such as replication competence, vector integration, and vector shedding. In addition, for many CGTPs, the value of nonclinical studies is largely limited to providing proof of concept, and the first meaningful data relating to appropriate dosing, safety parameters, and validity of surrogate or true determinants of efficacy must come from carefully designed clinical trials in patients. Addressing these numerous challenges requires application of various risk mitigation strategies and meeting regulatory expectations specifically adapted to the product types. Regulatory cooperation and harmonisation at an international level are essential for progress in the development and commercialisation of these products. However, particularly in the area of cell therapy, new regulatory paradigms may be needed to harness the benefits of clinical progress in situations where the resources and motivation to pursue a typical drug product approval pathway may be lacking.
Keywords: CTO Regulations; Health Canada; More than minimally manipulated; Regulation of cell therapy; Regulation of gene therapy; Safety of Human Cells, Tissues and Organs for Transplantation Regulations.
Similar articles
-
Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products.Adv Exp Med Biol. 2023;1430:91-116. doi: 10.1007/978-3-031-34567-8_6. Adv Exp Med Biol. 2023. PMID: 37526844 Review.
-
Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.Adv Exp Med Biol. 2015;871:73-85. doi: 10.1007/978-3-319-18618-4_4. Adv Exp Med Biol. 2015. PMID: 26374213 Review.
-
Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.Adv Exp Med Biol. 2015;871:163-79. doi: 10.1007/978-3-319-18618-4_9. Adv Exp Med Biol. 2015. PMID: 26374218 Review.
-
Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.Adv Exp Med Biol. 2015;871:195-212. doi: 10.1007/978-3-319-18618-4_11. Adv Exp Med Biol. 2015. PMID: 26374220 Review.
-
Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.Adv Exp Med Biol. 2015;871:103-30. doi: 10.1007/978-3-319-18618-4_6. Adv Exp Med Biol. 2015. PMID: 26374215 Review.
Cited by
-
Efficient Nonviral Transfection of Human Bone Marrow Mesenchymal Stromal Cells Shown Using Placental Growth Factor Overexpression.Stem Cells Int. 2018 Dec 24;2018:1310904. doi: 10.1155/2018/1310904. eCollection 2018. Stem Cells Int. 2018. PMID: 30675166 Free PMC article.
-
Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species.Front Cell Dev Biol. 2021 Feb 16;9:632717. doi: 10.3389/fcell.2021.632717. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33665190 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical